This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (54)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

A Clinical Study

Hossein A. Ghanbari, PhD; Barney E. Miller, PhD; Henry J. Haigler, PhD; Mihaly Arato, MD; Garth Bissette, PhD; Peter Davies, PhD; Charles B. Nemeroff, MD, PhD; Elaine K. Perry, PhD; Robert Perry, MD; Rivka Ravid, PhD; Dick F. Swaab, MD, PhD; William O. Whetsell, MD; Frank P. Zemlan, PhD

JAMA. 1990;263(21):2907-2910.

Abstract
The concentration of Alzheimer's disease—associated protein (ADAP) was measured in postmortem brain tissue samples of temporal or frontal cortex from 111 human brains using a sandwich immunoassay. Alzheimer's disease—associated protein has three major ALZ-50—reactive subunits, including A-68. This assay utilizes ALZ-50 and a rabbit antibody raised against a highly ADAP-enriched brain protein fraction. The frequently observed cross-reactivity of ALZ-50 with normal brain components in direct immunoassays is minimized by this configuration. There were 27 normal controls, 28 neurologic disease controls, and 56 Alzheimer's disease cases. The normal control and neurologic disease control cases had essentially no detectable level of ADAP, while ADAP was clearly detected in 85.7% of the Alzheimer's disease cases. Clinical dementia, neuritic plaques, and old age per se are not correlated with increased ADAP levels. This biochemical assay of ADAP may prove to be helpful as an adjunct in the clinicopathologic diagnosis of Alzheimer's disease.

(JAMA. 1990;263:2907-2910)

Author Affiliations
From Abbott Laboratories, Abbott Park, Ill (Drs Ghanbari, Miller, and Haigler); the Pathochemical Laboratory, National Institute for Nervous and Mental Diseases, Budapest, Hungary (Dr Arato); the Department of Psychiatry, Duke University Medical Center, Durham, NC (Drs Bissette and Nemeroff); the Department of Pathology, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY (Dr Davies); the Medical Research Council Neurochemical Pathology Unit and the Department of Neuropathology, Newcastle General Hospital, Newcastle Upon Tyne, England (Drs E. Perry and R. Perry); The Netherlands Institute for Brain Research, Amsterdam (Drs Ravid and Swaab); the Department of Neuropathology, Vanderbilt University, Nashville, Tenn (Dr Whetsell); and the Division of Geriatrics, University of Cincinnati (Ohio) College of Medicine (Dr Zemlan)

Footnotes
Reprint requests to Abbott Laboratories, Neuropsychiatric Markers R&D, D-9RR, AP20, Abbott Park, IL 60064 (Dr Ghanbari).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Correlation of rCBF (SPECT), CSF tau, and congnitive function in patients with dementia of the Alzheimer's type, other types of dementia, and congrol subjects
Tsolaki et al.
AM J ALZHEIMERS DIS OTHER DEMEN 2001;16:21-31.
ABSTRACT  

The Preeminent Role of Neuropeptide Systems in the Early Pathophysiology of Alzheimer Disease: Up With Corticotropin-Releasing Factor, Down With Acetylcholine
Nemeroff
Arch Gen Psychiatry 1999;56:991-992.
FULL TEXT  

Alzheimer Disease: Report of the Council on Scientific Affairs
Guttman et al.
Arch Fam Med 1999;8:347-353.
ABSTRACT | FULL TEXT  

The Structural Basis of Monoclonal Antibody Alz50's Selectivity for Alzheimer's Disease Pathology
Carmel et al.
J. Biol. Chem. 1996;271:32789-32795.
ABSTRACT | FULL TEXT  

Resampling Techniques in the Analysis of Non-binormal ROC Data
Mossman
Med Decis Making 1995;15:358-366.
ABSTRACT  

Classifying Binormal Diagnostic Tests Using Separation - Asymmetry Diagrams with Constant-performance Curves
Somoza
Med Decis Making 1994;14:157-168.
ABSTRACT  

Reliability and Usefulness of a New Immunochemical Assay for Alzheimer's Disease
Chui et al.
Arch Neurol 1993;50:57-63.
ABSTRACT  

Alterations in Alzheimer's Disease--Associated Protein in Alzheimer's Disease Frontal and Temporal Cortex
Bissette et al.
Arch Gen Psychiatry 1991;48:1009-1012.
ABSTRACT  

Quantitative Assessment of ALZ-50 Immunoreactivity in Alzheimer's Disease
Hyman et al.
J Geriatr Psychiatry Neurol 1991;4:231-235.
ABSTRACT  

A BIOCHEMICAL ASSAY FOR ALZHEIMER'S DISEASE
JWatch General 1990;1990:1-1.
FULL TEXT